WHO lists Sinopharm’s COVID-19 vaccine for emergency use
1
The inactivated Vero Cell COVID-19 vaccine is now eligible for global rollout alongside the four other vaccines with World Health Organization Emergency Use Listing.
The World Health Organization (WHO) has listed Sinopharm’s Vero Cell COVID-19 vaccine for emergency use, allowing it to be rolled out globally. Vero Cell is produced by Beijing Bio-Institute of Biological Products Co Ltd, a subsidiary of China National Biotec Group (CNBG).
“The addition of this vaccine has the potential to rapidly accelerate COVID-19 vaccine access for countries seeking to protect health workers and populations at risk,” commented Dr Mariângela Simão, WHO Assistant-Director General for Access to Health Products. “We urge the manufacturer to participate in the COVAX Facility and contribute to the goal of more equitable vaccine distribution.”
May 06 2021
Abbott has announced it now has a CE Mark for use of its Panbio™ COVID-19 Ag Rapid Test Device to detect the SARS-COV-2 virus in children age 15 years and younger. The CE Mark is based on the first-ever study focused on the performance of a rapid antigen test on children, including infants.
Abbott has received a CE Mark for the use of Panbio COVID-19 Ag with a nasal swab in asymptomatic and symptomatic individuals and for self-collection of samples under the supervision of trained professionals. The test with these performance data has also been added to the World Health Organisation s Emergency Use Listing (WHO EUL).
Hyderabad’s Biological E set to give fourth vaccine for India
By M Somasekhar| Updated: 23rd April 2021 9:13 pm IST
M Somasekhar
Hyderabad: Biological E, the country’s first manufacturer of vaccines in the private sector is all set to launch India’s fourth vaccine against COVID 19 by August 2021.
According to the Indian Council of Medical Research( ICMR) , Biological E is testing a two-dose vaccine similar to ‘Covaxin’, made by Bharat Biotech, another Hyderabad -based, vaccine maker.
The Niti Aayog member (health) Dr V K Paul recently said, “Biological E has finished phase-1/2 trials. They are submitting the data in the next few days after which they will initiate phase-3 trials of the vaccine.”
Read more about United States to help India s Biological E make 1 billion vaccine doses on Business Standard. The so-called Quad group agreed to expand efforts to ramp up vaccine manufacturing in the region